Aegle Therapeutics is a first-in-class, phase 1/2a biotechnology company isolating extracellular vesicles. Aegle believes its EV therapy has the potential for functional regeneration and organization of complex tissue structures that can accelerate and enhance healing, reduce scarring, minimize contraction and improve overall cosmesis.